Edward M. Kaye, MD

February 26th, 2024|Categories: Featured Members|

Edward M. Kaye, M.D. Chief Executive Officer and Director of Stoke Therapeutics How did you become interested in the field? My interest in genetic medicine began as a biochemical geneticist and pediatric neurologist. Back in the 1990s, when I was treating patients, I saw first-hand ...

2022 OTS Lifetime Achievement Award Winner Sudhir Agrawal, D.Phil.

February 22nd, 2024|Categories: Lifetime Achievement Award|

Sudhir Agrawal, D.Phil.Founder and President, Arnay SciencesDr. Agrawal is the founder and President of Arnay Sciences, a life science research company pursuing RNA therapeutics. Dr. Agrawal started his work on antisense in the late eighties in the laboratory of Paul Zamecnik, a pioneer of antisense ...

Follow-up Data Confirms That Inclisiran Provides Long-Term Reduction of LDL-Cholesterol

February 21st, 2024|Categories: Perspectives on Current Science|

Cardiovascular disease is the leading cause of death in the United States, exceeding all types of cancer, unintentional injury, and stroke combined. However, updated data from Novartis's open-label trial shows promising long-term results for inclisiran (Leqvio), the first and only small interfering RNA (siRNA) ...

Base Editing in Clinical Trials to Treat Acute Lymphoblastic Leukemia

January 23rd, 2024|Categories: Perspectives on Current Science|

Base editing has experienced a rapid rise in use since it first came on the scene in 2016, with multiple trials underway, testing its ability to treat conditions with precise, single-letter changes to DNA. The technique presents a potentially more accurate and safer method ...

Go to Top